Altimmune, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:ALT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 157.26 M190.35 M218.45 M279.93 M335.63 M527.21 M Total liabilities 15.1 M28.98 M32.85 M55.04 M51.64 M53 M Total equity 142.16 M161.37 M185.6 M224.89 M283.99 M474.21 M Total liabilities & shareholders' equities 157.26 M190.35 M218.45 M279.93 M335.63 M527.21 M Total debt —14.33 M14.45 M34.29 M34.51 M34.74 M Net debt —14.33 M-196.33 M-239.17 M-297.04 M-291.54 M

News

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses